抗凝血酶(AT)單克隆抗體
Monoclonal Antibody to Antithrombin (AT)
AT3; ATIII; SERPINC1; Anti-Thrombin Antibodies; Serpin Peptidase Inhibitor Clade C Member 1; Coding Sequence Signal Peptide Antithrombin Part 1
- 編號UMAC313Hu27
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源單抗制備
- 宿主小鼠
- 效價(克隆號)C1
- Ig亞型 IgG2b Kappa
- 純化方式蛋白A + 蛋白G親和純化
- 標(biāo)記物無標(biāo)記物
- 免疫原 RPC313Hu01-抗凝血酶(AT)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度1mg/ml
- 且適物種-
- 應(yīng)用WB; IHC; ICC/IF
如果抗體需用于流式細胞術(shù)，請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 344 ¥ 802 ¥ 1146 ¥ 2865 ¥ 11460
- 欲了解實際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
DAB staining on IHC-P; Sample: Human Kidney Tissue; Primary Ab: 20μg/ml Mouse Anti-Human AT Antibody Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody (Catalog: SAA544Mu19)
-
DAB staining on IHC-P;
Sample: Human Liver Tissue;
Primary Ab: 20μg/ml Mouse Anti-Human AT Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu19) -
DAB staining on IHC-P;
Sample: Human Spleen Tissue;
Primary Ab: 10μg/ml Mouse Anti-Human AT Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu19) -
AF488 staining on IF;
Sample: U2OS cell
Primary Ab: 20μg/ml Mouse Anti-Human AT Antibody
Second Ab: 2μg/ml AF488-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu11)
-
Western Blot; Sample: Lane1: Human Serum; Lane2: Human Plasma; Lane3: Human Lung lysate; Lane4: Human Placenta lysate Primary Ab: 3μg/ml Mouse Anti-Human AT Antibody Second Ab: 0.2μg/mL HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody (Catalog: SAA544Mu19)
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
特異性
該抗體是針對AT的小鼠單克隆抗體。在免疫組織化學(xué)染色和免疫印跡實驗中能識別AT。
用法
Western blotting: 0.5-3μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲，損失率低于5%。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| UNPC313Hu01 | 抗凝血酶(AT)天然蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPC313Hu01 | 抗凝血酶(AT)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPC313Hu03 | 抗凝血酶(AT)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UEPC313Hu61 | 抗凝血酶(AT)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPC313Hu01 | 抗凝血酶(AT)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPC313Hu02 | 抗凝血酶(AT)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPC313Hu61 | 抗凝血酶(AT)活性蛋白 | Cell?culture;?Activity?Assays. |
| UPAC313Hu01 | 抗凝血酶(AT)多克隆抗體 | WB; IHC |
| UPAC313Hu02 | 抗凝血酶(AT)多克隆抗體 | WB; IHC |
| UPAC313Hu03 | 抗凝血酶(AT)多克隆抗體 | IHC |
| ULAC313Hu81 | 抗凝血酶(AT)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| ULAC313Hu71 | 抗凝血酶(AT)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| UMAC313Hu21 | 抗凝血酶(AT)單克隆抗體 | WB; IHC |
| UMAC313Hu27 | 抗凝血酶(AT)單克隆抗體 | WB; IHC; ICC/IF |
| UMAC313Hu29 | 抗凝血酶(AT)單克隆抗體 | WB; IHC |
| UMAC313Hu23 | 抗凝血酶(AT)單克隆抗體 | WB; IHC |
| UMAC313Hu24 | 抗凝血酶(AT)單克隆抗體 | WB; IHC |
| UMAC313Hu26 | 抗凝血酶(AT)單克隆抗體 | WB; IHC |
| UMAC313Hu22 | 抗凝血酶(AT)單克隆抗體 | WB; IHC |
| UMAC313Hu28 | 抗凝血酶(AT)單克隆抗體 | IHC |
| UMAC313Hu25 | 抗凝血酶(AT)單克隆抗體 | WB; IHC |
| UFAC313Hu02 | 抗抗凝血酶(AT)單克隆抗體 | FCM |
| UFAC313Hu04 | 抗抗凝血酶(AT)單克隆抗體 | FCM |
| UFAC313Hu08 | 抗抗凝血酶(AT)單克隆抗體 | FCM |
| ULAC313Hu72 | 抗凝血酶(AT)單克隆抗體(生物素標(biāo)記) | IHC |
| ULAC313Hu82 | 抗凝血酶(AT)單克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| USEC313Hu | 抗凝血酶(AT)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USCC313Hu | 抗凝血酶(AT)檢測試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| ULMC313Hu | 抗凝血酶(AT)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UKSC313Hu01 | 抗凝血酶(AT)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻
| 雜志 | 參考文獻 |
| Thromb Res | Thalidomide and multiple myeloma serum synergistically induce a hemostatic imbalance in endothelial cells in vitro [PubMed: 25840743] |
| Neurotherapeutics | iTRAQ-Based Quantitative Proteomics Reveals the New Evidence Base for Traumatic Brain Injury Treated with Targeted Temperature Management [pubmed:29247448] |
| Journal of?Clinical?and Aesthetic Dermatology | Detection of Angiotensin II and AT1 Receptor Concentrations in Keloid and Hypertrophic Scar. [] |
| 博士論文 | An Agile Approach to Novel Recombinant Antithrombin Production for use in Biologics Development [] |
留言咨詢
